Cathepsin K inhibitors

A novel target but promising approach in the treatment of osteoporosis

Asadul Mazid Helali, Farhana Matin Iti, Isa Naina Mohamed

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Osteoporosis is a pathologic process characterized by low bone mass with skeletal fragility and an increased risk of fracture. It occurs due to an imbalance between bone resorption and formation. Although current antiresorptive therapy halts bone loss, it does not cure the condition as it also inhibits bone formation. Recent preclinical and clinical trials suggest that the inhibition of resorption by cathepsin K inhibitors increases bone formation. Cathepsin K is a papainlike cysteine protease with high potent collagenase activity and predominantly expressed in osteoclasts. While allowing demineralization, cathepsin K inhibitors suppress the degradation of type I collagen (the major organic matrix of bone) and thus enhancing bone formation. Many of these inhibitors have passed preclinical studies and are presently in clinical trials at different stages of advancement. This review explores the promising role of cathepsin K as a novel antiresorptive for the treatment of osteoporosis.

Original languageEnglish
Pages (from-to)1591-1600
Number of pages10
JournalCurrent Drug Targets
Volume14
Issue number13
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Cathepsin K
Osteogenesis
Osteoporosis
Bone
Clinical Trials
Bone and Bones
Bone Matrix
Cysteine Proteases
Collagenases
Osteoclasts
Pathologic Processes
Bone Resorption
Collagen Type I
Corrosion inhibitors
Degradation

Keywords

  • Bone remodeling
  • Bone resorption
  • Bone turnover markers
  • Cathepsin K
  • Osteoclast
  • Osteoporosis
  • Selective cathepsin K inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Cathepsin K inhibitors : A novel target but promising approach in the treatment of osteoporosis. / Helali, Asadul Mazid; Iti, Farhana Matin; Naina Mohamed, Isa.

In: Current Drug Targets, Vol. 14, No. 13, 12.2013, p. 1591-1600.

Research output: Contribution to journalArticle

Helali, Asadul Mazid ; Iti, Farhana Matin ; Naina Mohamed, Isa. / Cathepsin K inhibitors : A novel target but promising approach in the treatment of osteoporosis. In: Current Drug Targets. 2013 ; Vol. 14, No. 13. pp. 1591-1600.
@article{11ef3cc6bdc84e60a68f2742da15c2ab,
title = "Cathepsin K inhibitors: A novel target but promising approach in the treatment of osteoporosis",
abstract = "Osteoporosis is a pathologic process characterized by low bone mass with skeletal fragility and an increased risk of fracture. It occurs due to an imbalance between bone resorption and formation. Although current antiresorptive therapy halts bone loss, it does not cure the condition as it also inhibits bone formation. Recent preclinical and clinical trials suggest that the inhibition of resorption by cathepsin K inhibitors increases bone formation. Cathepsin K is a papainlike cysteine protease with high potent collagenase activity and predominantly expressed in osteoclasts. While allowing demineralization, cathepsin K inhibitors suppress the degradation of type I collagen (the major organic matrix of bone) and thus enhancing bone formation. Many of these inhibitors have passed preclinical studies and are presently in clinical trials at different stages of advancement. This review explores the promising role of cathepsin K as a novel antiresorptive for the treatment of osteoporosis.",
keywords = "Bone remodeling, Bone resorption, Bone turnover markers, Cathepsin K, Osteoclast, Osteoporosis, Selective cathepsin K inhibitors",
author = "Helali, {Asadul Mazid} and Iti, {Farhana Matin} and {Naina Mohamed}, Isa",
year = "2013",
month = "12",
doi = "10.2174/13894501113149990202",
language = "English",
volume = "14",
pages = "1591--1600",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Cathepsin K inhibitors

T2 - A novel target but promising approach in the treatment of osteoporosis

AU - Helali, Asadul Mazid

AU - Iti, Farhana Matin

AU - Naina Mohamed, Isa

PY - 2013/12

Y1 - 2013/12

N2 - Osteoporosis is a pathologic process characterized by low bone mass with skeletal fragility and an increased risk of fracture. It occurs due to an imbalance between bone resorption and formation. Although current antiresorptive therapy halts bone loss, it does not cure the condition as it also inhibits bone formation. Recent preclinical and clinical trials suggest that the inhibition of resorption by cathepsin K inhibitors increases bone formation. Cathepsin K is a papainlike cysteine protease with high potent collagenase activity and predominantly expressed in osteoclasts. While allowing demineralization, cathepsin K inhibitors suppress the degradation of type I collagen (the major organic matrix of bone) and thus enhancing bone formation. Many of these inhibitors have passed preclinical studies and are presently in clinical trials at different stages of advancement. This review explores the promising role of cathepsin K as a novel antiresorptive for the treatment of osteoporosis.

AB - Osteoporosis is a pathologic process characterized by low bone mass with skeletal fragility and an increased risk of fracture. It occurs due to an imbalance between bone resorption and formation. Although current antiresorptive therapy halts bone loss, it does not cure the condition as it also inhibits bone formation. Recent preclinical and clinical trials suggest that the inhibition of resorption by cathepsin K inhibitors increases bone formation. Cathepsin K is a papainlike cysteine protease with high potent collagenase activity and predominantly expressed in osteoclasts. While allowing demineralization, cathepsin K inhibitors suppress the degradation of type I collagen (the major organic matrix of bone) and thus enhancing bone formation. Many of these inhibitors have passed preclinical studies and are presently in clinical trials at different stages of advancement. This review explores the promising role of cathepsin K as a novel antiresorptive for the treatment of osteoporosis.

KW - Bone remodeling

KW - Bone resorption

KW - Bone turnover markers

KW - Cathepsin K

KW - Osteoclast

KW - Osteoporosis

KW - Selective cathepsin K inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84887387835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887387835&partnerID=8YFLogxK

U2 - 10.2174/13894501113149990202

DO - 10.2174/13894501113149990202

M3 - Article

VL - 14

SP - 1591

EP - 1600

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 13

ER -